Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.

MLA

Wurzer, Alexander, et al. “Preclinical Comparison of [177Lu]Lu-RhPSMA-10.1 and [177Lu]Lu-RhPSMA-10.2 for Endoradiotherapy of Prostate Cancer: Biodistribution and Dosimetry Studies.” EJNMMI Radiopharmacy & Chemistry, vol. 9, no. 1, Feb. 2024, pp. 1–14. EBSCOhost, https://doi.org/10.1186/s41181-024-00246-2.

APA

Wurzer, A., De Rose, F., Fischer, S., Schwaiger, M., Weber, W., Nekolla, S., Wester, H.-J., Eiber, M., & D’Alessandria, C. (2024). Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies. EJNMMI Radiopharmacy & Chemistry, 9(1), 1–14. https://doi.org/10.1186/s41181-024-00246-2

Chicago

Wurzer, Alexander, Francesco De Rose, Sebastian Fischer, Markus Schwaiger, Wolfgang Weber, Stephan Nekolla, Hans-Jürgen Wester, Matthias Eiber, and Calogero D’Alessandria. 2024. “Preclinical Comparison of [177Lu]Lu-RhPSMA-10.1 and [177Lu]Lu-RhPSMA-10.2 for Endoradiotherapy of Prostate Cancer: Biodistribution and Dosimetry Studies.” EJNMMI Radiopharmacy & Chemistry 9 (1): 1–14. doi:10.1186/s41181-024-00246-2.